

# Prescription for Cardiovascular Protection with diabetes

Prescriber's Name: \_\_\_\_\_

Address: \_\_\_\_\_

Tel: \_\_\_\_\_

Fax: \_\_\_\_\_

Patient's Name: \_\_\_\_\_

Address: \_\_\_\_\_

Tel: \_\_\_\_\_

STEP 1:	STEP 2: Choose Cardiovascular protection agent(s) from the following list		Dosing						
<p><b>Is the patient...</b></p> <ul style="list-style-type: none"> <li>- age &gt;40?</li> <li>OR</li> <li>- age &gt;30, and diabetes &gt;15 years?</li> <li>OR</li> <li>- warranted for statin therapy based on the Canadian Cardiovascular Society Lipid Guidelines?</li> </ul> <p style="text-align: right;"><b>YES</b> →</p>	<p><b>Statin</b></p>	<p style="text-align: center;"><b>STATIN</b></p> <table border="0"> <tr> <td> <input type="checkbox"/> <b>Atorvastatin</b> (Lipitor®)  <input type="checkbox"/> 10 mg (start 10 mg OD)  <input type="checkbox"/> 20 mg  <input type="checkbox"/> 40 mg  <input type="checkbox"/> 80 mg (max 80 mg OD)                 </td> <td> <input type="checkbox"/> <b>Fluvastatin</b> (Lescol®)  <input type="checkbox"/> 20 mg (start 20 mg OD)  <input type="checkbox"/> 40 mg  <input type="checkbox"/> 80 mg (max 80 mg OD)                 </td> <td> <input type="checkbox"/> <b>Lovastatin</b> (Mecavor®)  <input type="checkbox"/> 20 mg (start 20 mg OD)  <input type="checkbox"/> 40 mg (max 80 mg OD)                 </td> </tr> <tr> <td> <input type="checkbox"/> <b>Pravastatin</b> (Pravachol®)  <input type="checkbox"/> 10 mg (start 10 mg OD)  <input type="checkbox"/> 20 mg  <input type="checkbox"/> 40 mg  <input type="checkbox"/> 80 mg (max 80 mg OD)                 </td> <td> <input type="checkbox"/> <b>Rosuvastatin</b> (Crestor®)  <input type="checkbox"/> 5 mg  <input type="checkbox"/> 10 mg (start 10 mg OD)  <input type="checkbox"/> 20 mg  <input type="checkbox"/> 40 mg (max 40 mg OD)                 </td> <td> <input type="checkbox"/> <b>Simvastatin</b> (Zocor®)  <input type="checkbox"/> 10 mg (start 10 mg OD)  <input type="checkbox"/> 20 mg  <input type="checkbox"/> 40 mg (max 80 mg OD)                 </td> </tr> </table>	<input type="checkbox"/> <b>Atorvastatin</b> (Lipitor®) <input type="checkbox"/> 10 mg (start 10 mg OD) <input type="checkbox"/> 20 mg <input type="checkbox"/> 40 mg <input type="checkbox"/> 80 mg (max 80 mg OD)	<input type="checkbox"/> <b>Fluvastatin</b> (Lescol®) <input type="checkbox"/> 20 mg (start 20 mg OD) <input type="checkbox"/> 40 mg <input type="checkbox"/> 80 mg (max 80 mg OD)	<input type="checkbox"/> <b>Lovastatin</b> (Mecavor®) <input type="checkbox"/> 20 mg (start 20 mg OD) <input type="checkbox"/> 40 mg (max 80 mg OD)	<input type="checkbox"/> <b>Pravastatin</b> (Pravachol®) <input type="checkbox"/> 10 mg (start 10 mg OD) <input type="checkbox"/> 20 mg <input type="checkbox"/> 40 mg <input type="checkbox"/> 80 mg (max 80 mg OD)	<input type="checkbox"/> <b>Rosuvastatin</b> (Crestor®) <input type="checkbox"/> 5 mg <input type="checkbox"/> 10 mg (start 10 mg OD) <input type="checkbox"/> 20 mg <input type="checkbox"/> 40 mg (max 40 mg OD)	<input type="checkbox"/> <b>Simvastatin</b> (Zocor®) <input type="checkbox"/> 10 mg (start 10 mg OD) <input type="checkbox"/> 20 mg <input type="checkbox"/> 40 mg (max 80 mg OD)	<p><b>Dosing:</b> see start and maximum doses listed for each statin</p>
<input type="checkbox"/> <b>Atorvastatin</b> (Lipitor®) <input type="checkbox"/> 10 mg (start 10 mg OD) <input type="checkbox"/> 20 mg <input type="checkbox"/> 40 mg <input type="checkbox"/> 80 mg (max 80 mg OD)		<input type="checkbox"/> <b>Fluvastatin</b> (Lescol®) <input type="checkbox"/> 20 mg (start 20 mg OD) <input type="checkbox"/> 40 mg <input type="checkbox"/> 80 mg (max 80 mg OD)	<input type="checkbox"/> <b>Lovastatin</b> (Mecavor®) <input type="checkbox"/> 20 mg (start 20 mg OD) <input type="checkbox"/> 40 mg (max 80 mg OD)						
<input type="checkbox"/> <b>Pravastatin</b> (Pravachol®) <input type="checkbox"/> 10 mg (start 10 mg OD) <input type="checkbox"/> 20 mg <input type="checkbox"/> 40 mg <input type="checkbox"/> 80 mg (max 80 mg OD)	<input type="checkbox"/> <b>Rosuvastatin</b> (Crestor®) <input type="checkbox"/> 5 mg <input type="checkbox"/> 10 mg (start 10 mg OD) <input type="checkbox"/> 20 mg <input type="checkbox"/> 40 mg (max 40 mg OD)	<input type="checkbox"/> <b>Simvastatin</b> (Zocor®) <input type="checkbox"/> 10 mg (start 10 mg OD) <input type="checkbox"/> 20 mg <input type="checkbox"/> 40 mg (max 80 mg OD)							
<p><b>Is the patient...</b></p> <ul style="list-style-type: none"> <li>- age &gt;55 with additional CV risk factors?</li> </ul> <p><b>Does the patient have microvascular disease?</b></p> <ul style="list-style-type: none"> <li>- Retinopathy</li> <li>- Kidney disease (ACR&gt;2.0)</li> <li>- Neuropathy</li> </ul> <p style="text-align: right;"><b>YES</b> →</p>	<p><b>Statin + ACEi or ARB</b></p>	<p style="text-align: center;"><b>ACE INHIBITORS</b></p> <table border="0"> <tr> <td> <input type="checkbox"/> <b>Perindopril</b> (Aceon®, Coversyl®)  <input type="checkbox"/> 2 mg  <input type="checkbox"/> 4 mg (start 4 mg OD)  <input type="checkbox"/> 8 mg (max 16 mg OD)                 </td> <td> <input type="checkbox"/> <b>Ramipril</b> (Altace®)  <input type="checkbox"/> 1.25 mg  <input type="checkbox"/> 2.5 mg (start 2.5 mg OD)  <input type="checkbox"/> 5 mg  <input type="checkbox"/> 10 mg (max 20 mg OD)                 </td> </tr> </table>	<input type="checkbox"/> <b>Perindopril</b> (Aceon®, Coversyl®) <input type="checkbox"/> 2 mg <input type="checkbox"/> 4 mg (start 4 mg OD) <input type="checkbox"/> 8 mg (max 16 mg OD)	<input type="checkbox"/> <b>Ramipril</b> (Altace®) <input type="checkbox"/> 1.25 mg <input type="checkbox"/> 2.5 mg (start 2.5 mg OD) <input type="checkbox"/> 5 mg <input type="checkbox"/> 10 mg (max 20 mg OD)	<p style="text-align: center;"><b>ARB</b></p> <table border="0"> <tr> <td> <input type="checkbox"/> <b>Telmisartan</b> (Micardis®)  <input type="checkbox"/> 20 mg  <input type="checkbox"/> 40 mg (start 40 mg OD)  <input type="checkbox"/> 80 mg (max 80 mg OD)                 </td> </tr> </table>	<input type="checkbox"/> <b>Telmisartan</b> (Micardis®) <input type="checkbox"/> 20 mg <input type="checkbox"/> 40 mg (start 40 mg OD) <input type="checkbox"/> 80 mg (max 80 mg OD)	<p><b>Dosing:</b> see start and maximum doses listed for each ACEi</p> <p><b>ACEi:</b> see precautions for dosing in kidney and liver disease on next page. Increase doses at 2-3 week intervals.</p>		
<input type="checkbox"/> <b>Perindopril</b> (Aceon®, Coversyl®) <input type="checkbox"/> 2 mg <input type="checkbox"/> 4 mg (start 4 mg OD) <input type="checkbox"/> 8 mg (max 16 mg OD)	<input type="checkbox"/> <b>Ramipril</b> (Altace®) <input type="checkbox"/> 1.25 mg <input type="checkbox"/> 2.5 mg (start 2.5 mg OD) <input type="checkbox"/> 5 mg <input type="checkbox"/> 10 mg (max 20 mg OD)								
<input type="checkbox"/> <b>Telmisartan</b> (Micardis®) <input type="checkbox"/> 20 mg <input type="checkbox"/> 40 mg (start 40 mg OD) <input type="checkbox"/> 80 mg (max 80 mg OD)									
<p><b>Does the patient have cardiovascular disease?</b></p> <ul style="list-style-type: none"> <li>- Cardiac ischemia (silent or overt)</li> <li>- Peripheral arterial disease</li> <li>- Cerebrovascular/carotid disease</li> </ul> <p style="text-align: right;"><b>YES</b> →</p>	<p><b>Statin + ACEi or ARB + ASA</b></p>	<p style="text-align: center;"><b>ASA (if CVD)</b></p> <table border="0"> <tr> <td> <input type="checkbox"/> <b>ASA</b>  <input type="checkbox"/> 81 mg  <input type="checkbox"/> 162 mg                 </td> <td> <input type="checkbox"/> <b>Clopidogrel</b> (Plavix®) for those unable able to tolerate ASA  <input type="checkbox"/> 75 mg                 </td> </tr> </table>	<input type="checkbox"/> <b>ASA</b> <input type="checkbox"/> 81 mg <input type="checkbox"/> 162 mg	<input type="checkbox"/> <b>Clopidogrel</b> (Plavix®) for those unable able to tolerate ASA <input type="checkbox"/> 75 mg					
<input type="checkbox"/> <b>ASA</b> <input type="checkbox"/> 81 mg <input type="checkbox"/> 162 mg	<input type="checkbox"/> <b>Clopidogrel</b> (Plavix®) for those unable able to tolerate ASA <input type="checkbox"/> 75 mg								
<p style="text-align: center;"><b>YES</b> ↓</p> <p><b>AND</b> the patient has type 2 diabetes and is <b>NOT</b> at glycemic target</p> <p style="text-align: right;"><b>YES</b> →</p>	<p><b>Statin + ACEi or ARB + ASA + SGLT-2i or GLP-1ra</b></p>	<p style="text-align: center;"><b>SGLT-2 inhibitor</b></p> <table border="0"> <tr> <td> <input type="checkbox"/> <b>Canagliflozin</b> (Invokana®)  <input type="checkbox"/> 100 mg (start 100 mg OD)  <input type="checkbox"/> 300 mg (max 300 mg OD)                 </td> <td> <input type="checkbox"/> <b>Empagliflozin</b> (Jardiance®)  <input type="checkbox"/> 10 mg (start 10 mg OD)  <input type="checkbox"/> 25 mg (max 25 mg OD)                 </td> </tr> </table> <p style="text-align: center;"><b>GLP-1 receptor agonist</b></p> <table border="0"> <tr> <td> <input type="checkbox"/> <b>Liraglutide</b> (Victoza®)  <input type="checkbox"/> 0.6 mg (start 0.6 mg OD)  <input type="checkbox"/> 1.2 mg  <input type="checkbox"/> 1.8 mg (max 1.8 mg OD)                 </td> </tr> </table>	<input type="checkbox"/> <b>Canagliflozin</b> (Invokana®) <input type="checkbox"/> 100 mg (start 100 mg OD) <input type="checkbox"/> 300 mg (max 300 mg OD)	<input type="checkbox"/> <b>Empagliflozin</b> (Jardiance®) <input type="checkbox"/> 10 mg (start 10 mg OD) <input type="checkbox"/> 25 mg (max 25 mg OD)	<input type="checkbox"/> <b>Liraglutide</b> (Victoza®) <input type="checkbox"/> 0.6 mg (start 0.6 mg OD) <input type="checkbox"/> 1.2 mg <input type="checkbox"/> 1.8 mg (max 1.8 mg OD)	<p><b>Starting dose:</b> lowest dose and titrate up Q 4 weeks. Check eGFR periodically; discontinue if eGFR &lt;30mL/min.</p> <p><b>See benefits and precautions on next page</b></p> <p><b>Starting dose:</b> Start at 0.6 mg s.c. OD, increase by 0.6 mg Q weekly until maximum dose reached. If nausea experienced, reduce dose down by 0.6 mg and use slower titration schedule (Q 2 – 3 weeks between increases)</p> <p><b>See benefits and precautions on next page</b></p>			
<input type="checkbox"/> <b>Canagliflozin</b> (Invokana®) <input type="checkbox"/> 100 mg (start 100 mg OD) <input type="checkbox"/> 300 mg (max 300 mg OD)	<input type="checkbox"/> <b>Empagliflozin</b> (Jardiance®) <input type="checkbox"/> 10 mg (start 10 mg OD) <input type="checkbox"/> 25 mg (max 25 mg OD)								
<input type="checkbox"/> <b>Liraglutide</b> (Victoza®) <input type="checkbox"/> 0.6 mg (start 0.6 mg OD) <input type="checkbox"/> 1.2 mg <input type="checkbox"/> 1.8 mg (max 1.8 mg OD)									

Signature: \_\_\_\_\_

Print Name: \_\_\_\_\_

Date: \_\_\_\_\_

License #: \_\_\_\_\_

## Cardiovascular protection targets & precautions for people with diabetes

### People with diabetes should be started on cardiovascular protection agents.

The following are suggestions for considerations in cardiovascular protection.

Clinical judgment must always be used as the suggestions may not apply to every patient.

**Lipid targets:** LDL-cholesterol <2.0 mmol/L or >50% reduction from baseline; Non-HDL <2.6 mmol/L; Apolipoprotein B <0.8 g/L

**BP targets:** <130/80 mmHg

**BG targets:** A1C <7.0% implemented early in the course of diabetes

**NOTE: among women with childbearing potential, ACEi, ARBs or statins should only be used if there is reliable contraception**

**Angiotension Converting Enzyme inhibitor (ACEi) & Angiotension II Receptor Blocker (ARB) are used to reduce CV risk in adults with type 1 or type 2 diabetes with any of the following:**

**a)** Clinical CVD;

**b)** Age >55 years with additional CV risk factors or

**c)** end organ damage (albuminuria, retinopathy, LVH), microvascular complications

Precautions: hypersensitivity; previous angioedema associated with ACEi therapy; impaired renal function; hyperkalemia; renal artery stenosis (bilateral or unilateral with a solitary functioning kidney); concomitant NSAID hypovolemia or dehydration; primary hyperaldosteronism; pregnancy or breastfeeding.

**NOTE: among women with childbearing potential, ACEi, ARBs or statins should only be used if there is reliable contraception**

**STATIN** therapy should be used to reduce CV risk in adults with type 1 or type 2 diabetes with any of the following:

**a)** Clinical CVD;

**b)** age >40 years;

**c)** age <40 years and 1 of the following: (i) diabetes duration >15 years and age >30; (ii) microvascular complications

Precautions: Impaired renal and hepatic function are risk factors for adverse effects with statins, e.g rhabdomyolysis. Active liver disease or unexplained transaminase elevations are contraindications to all statins.

**NOTE: among women with childbearing potential, ACEi, ARBs or statins should only be used if there is reliable contraception**

### ASA

In people with established CVD, low-dose ASA therapy (81–162 mg) should be used to prevent CV events

ASA should not be used routinely for the primary prevention of CVD events

Clopidogrel 75 mg may be used in people unable to tolerate ASA

Precautions: risk of stomach ulcers or bleeding

**SGLT-2 inhibitor or GLP-1 receptor agonist with demonstrated CV benefit: Indicated for use in patients with type 2 diabetes only** (if CVD and A1C not at target)

**SLGT-2 Precautions:** use with caution in renal impairment (will not cause harm, will just not be effective); monitor for DKA and euglycemia or mild hyperglycemia, should be held if unable to stay hydrated through diet, encourage 1 – 1.5 L of fluid intake per day. Increased risk of UTI and yeast infections.

**GLP-1 Precautions:** nausea; vomiting; injection site reactions; contraindicated in: renal failure; pancreatitis; medullary thyroid cell carcinoma; Multiple Endocrine Neoplasia Syndrome (MENS2) or T1DM, DKA, pregnancy, children; can increase heart rate by 7-8 bpm & prolong PR interval by 10 ms.

### Physical Activity

Physical activity is associated with improvement in CV outcomes and a reduction in CV and overall mortality in people with type 2 diabetes or IGT and CVD. Habitual, prolonged sitting is associated with increased risk of death and major cardiovascular events. People with diabetes should ideally accumulate a minimum of 150 minutes of moderate- to vigorous-intensity aerobic exercise each week, spread over at least 3 days of the week, with no more than 2 consecutive days without exercise, to improve glycemic control and to reduce risk of CVD and overall mortality.

### Diet

To reduce the risk of CVD, adults with diabetes should avoid trans fatty acids and consume less than 9% of total daily energy from saturated fatty acids replacing these fatty acids with polyunsaturated fatty acids, monounsaturated fatty acids, whole grains or low-Glycemic Index carbohydrates. The Mediterranean style diet and DASH diet have been shown to help manage diabetes and cardiovascular disease.

**Cardiovascular Protection Quick Link from Diabetes Canada** <http://guidelines.diabetes.ca/reduce-complications/risk-assessment>